| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2003PNAS..100.2420S |
| P356 | DOI | 10.1073/PNAS.0438031100 |
| P932 | PMC publication ID | 151356 |
| P698 | PubMed publication ID | 12601175 |
| P5875 | ResearchGate publication ID | 10887843 |
| P2093 | author name string | Richard D Kolodner | |
| Atsuko Yoshioka-Yamashita | |||
| Jean Y J Wang | |||
| Hideki Shimodaira | |||
| P2860 | cites work | The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage | Q22010200 |
| p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage | Q22010201 | ||
| MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability | Q22010995 | ||
| Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis | Q22122362 | ||
| 12/15-lipoxygenase translocation enhances site-specific actin polymerization in macrophages phagocytosing apoptotic cells | Q24291036 | ||
| Mutations of two PMS homologues in hereditary nonpolyposis colon cancer | Q24318484 | ||
| The mismatch repair system is required for S-phase checkpoint activation | Q24321503 | ||
| BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures | Q24606873 | ||
| Enhancement of MSH2-MSH3-mediated mismatch recognition by the yeast MLH1-PMS1 complex | Q27932428 | ||
| Eukaryotic DNA mismatch repair | Q27939116 | ||
| ATP-dependent assembly of a ternary complex consisting of a DNA mismatch and the yeast MSH2-MSH6 and MLH1-PMS1 protein complexes | Q27939412 | ||
| The DNA damage response: putting checkpoints in perspective | Q28131713 | ||
| Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis | Q28138604 | ||
| Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer | Q28294774 | ||
| MSH2 deficient mice are viable and susceptible to lymphoid tumours | Q28508486 | ||
| Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair | Q28508905 | ||
| Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine | Q28585239 | ||
| Mutation in the mismatch repair gene Msh6 causes cancer susceptibility | Q28592583 | ||
| Meiotic arrest and aneuploidy in MLH3-deficient mice | Q28593875 | ||
| ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair | Q28610858 | ||
| Microsatellite instability in cancer of the proximal colon | Q29620692 | ||
| Steady-state regulation of the human DNA mismatch repair system. | Q33896699 | ||
| Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene | Q33898040 | ||
| The role of mismatch repair in DNA damage-induced apoptosis. | Q33924716 | ||
| Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis | Q33960642 | ||
| DNA mismatch repair and genetic instability | Q34090778 | ||
| Functional interactions and signaling properties of mammalian DNA mismatch repair proteins | Q34425450 | ||
| The molecular basis of Turcot's syndrome | Q34662365 | ||
| p73: Friend or foe in tumorigenesis | Q34770297 | ||
| hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage | Q36538872 | ||
| Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct | Q37522716 | ||
| Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis | Q38293261 | ||
| Regulation of p73 by c-Abl through the p38 MAP kinase pathway. | Q40751506 | ||
| Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways | Q40855179 | ||
| Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. | Q40920177 | ||
| Apoptosis induced by overexpression of hMSH2 or hMLH1. | Q40943668 | ||
| A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system | Q40969894 | ||
| p73 is a simian [correction of human] p53-related protein that can induce apoptosis | Q41091013 | ||
| Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line | Q41174585 | ||
| Loss of DNA mismatch repair in acquired resistance to cisplatin | Q41189901 | ||
| MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast | Q42427955 | ||
| Clues to the pathogenesis of familial colorectal cancer | Q42622043 | ||
| Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae | Q47713981 | ||
| Drastic genetic instability of tumors and normal tissues in Turcot syndrome | Q48570250 | ||
| Genetic analysis of the mouse brain proteome | Q48651123 | ||
| DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. | Q50320380 | ||
| Heterozygous DNA mismatch repair gene PMS2-knockout mice are susceptible to intestinal tumor induction with N-methyl-N-nitrosourea. | Q53411510 | ||
| p63 and p73 are required for p53-dependent apoptosis in response to DNA damage | Q59065672 | ||
| The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin | Q71533749 | ||
| MSH2 and MSH6 are required for removal of adenine misincorporated opposite 8-oxo-guanine in S. cerevisiae | Q73075608 | ||
| DNA mismatch repair and cancer | Q74701340 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| DNA mismatch repair | Q2984243 | ||
| cisplatin | Q412415 | ||
| P304 | page(s) | 2420-5 | |
| P577 | publication date | 2003-03-04 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin | |
| P478 | volume | 100 |
| Q38266299 | A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression |
| Q24564010 | ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage |
| Q34820495 | Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q |
| Q36984707 | Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells |
| Q36859304 | Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis |
| Q34089685 | Cellular Responses to Cisplatin‐Induced DNA Damage |
| Q34659119 | Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients. |
| Q90149375 | Cisplatin-Based Chemotherapy of Human Cancers |
| Q37729428 | Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies |
| Q35978833 | Coordination of repair, checkpoint, and cell death responses to DNA damage |
| Q38174090 | Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer |
| Q36604609 | DDB2 gene disruption leads to skin tumors and resistance to apoptosis after exposure to ultraviolet light but not a chemical carcinogen |
| Q36525449 | DNA damage response in cisplatin-induced nephrotoxicity |
| Q36540658 | DNA mismatch repair and the DNA damage response |
| Q41175947 | DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis. |
| Q24647002 | DNA mismatch repair: molecular mechanism, cancer, and ageing |
| Q21195898 | Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer |
| Q35596120 | Diagnosing Lynch syndrome: is the answer in the mouth? |
| Q36670109 | Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis |
| Q45177408 | Exclusion of c-Abl from the Nucleus Restrains the p73 Tumor Suppression Function |
| Q35559704 | Folate deficiency, mismatch repair-dependent apoptosis, and human disease |
| Q39511907 | Genome Wide In silico Analysis of the Mismatch Repair Components of Plasmodium falciparum and Their Comparison with Human Host |
| Q58921526 | Gold(iii) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene |
| Q42284928 | History and pathogenesis of lynch syndrome |
| Q36375191 | Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells. |
| Q48227977 | Hypothesis: Possible role of retinoic acid therapy in patients with biallelic mismatch repair gene defects |
| Q42013225 | Identification of genetic susceptibility to childhood cancer through analysis of genes in parallel |
| Q35851987 | Identification of reproducible drug-resistance-related dysregulated genes in small-scale cancer cell line experiments. |
| Q24555745 | Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements |
| Q28074585 | Impact of DNA mismatch repair system alterations on human fertility and related treatments |
| Q37371661 | In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system |
| Q45458727 | Interaction studies of muts and mutl with DNA containing the major cisplatin lesion and its mismatched counterpart under equilibrium and nonequilibrium conditions |
| Q40147500 | Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines |
| Q36246487 | Lynch syndrome genes |
| Q33930068 | MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function |
| Q28262719 | Mechanisms and functions of DNA mismatch repair |
| Q97526961 | Mismatch Repair Pathway, Genome Stability and Cancer |
| Q33758325 | Mismatch repair proteins are activators of toxic responses to chromium-DNA damage |
| Q34723491 | Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair |
| Q34928405 | Multiple stress signals induce p73beta accumulation |
| Q34425503 | New insights into the link between DNA damage and apoptosis |
| Q38831231 | PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis |
| Q33201671 | Proteolysis of the mismatch repair protein MLH1 by caspase-3 promotes DNA damage-induced apoptosis |
| Q28274939 | RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage |
| Q36296744 | Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links |
| Q34236531 | Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells |
| Q37158252 | Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer |
| Q33533641 | Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3beta is implicated in the treatment of cervical carcinoma |
| Q36521428 | Structure and function of the components of the human DNA mismatch repair system |
| Q34382716 | TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. |
| Q28505153 | TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity |
| Q42856035 | The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response |
| Q36448284 | The multifaceted mismatch-repair system |
| Q40095644 | The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors |
| Q35076298 | Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer |
| Q24298905 | Thymosin beta 4 expression and nuclear transport are regulated by hMLH1 |
| Q38325797 | Transactivation-dependent and -independent regulation of p73 stability |
| Q37694831 | Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome |
| Q36399088 | Ubiquitin-dependent degradation of p73 is inhibited by PML. |
| Q37087404 | Versatile functions of p53 protein in multicellular organisms |
| Q33896065 | YAP accelerates Aβ(25-35)-induced apoptosis through upregulation of Bax expression by interaction with p73. |
| Q40527005 | c-Jun regulates the stability and activity of the p53 homologue, p73. |
| Q40325214 | p19ras interacts with and activates p73 by involving the MDM2 protein |
| Q89805472 | p53-Related Transcription Targets of TAp73 in Cancer Cells-Bona Fide or Distorted Reality? |
| Q38333104 | p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. |
| Q43010733 | p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes. |
Search more.